🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jinan
Clinical trial register · China

Clinical Trials in Jinan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Qilu Hospital of Shandong University114 Qianfoshan Hospital32 Shandong Cancer Hospital and Institute31 AstraZeneca26 Shandong University26
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Jinan

785 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
NCT07274774Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2
184
Jinan
2025-11-30
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
NCT07278336Ovarian Cancer
AbbVie
Phase 1
219
Guangzhou, Jinan, Shanghai
2025-11-27
Recruiting
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
NCT07362940Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd.
Phase 1/2
110
Beijing, Changsha, Jinan, Xiamen, Zhengzhou
2025-11-27
Recruiting
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
NCT07108270Neoplasms, Endometrial
GlaxoSmithKline
Phase 2
30
Jinan
2025-11-27
Recruiting
A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease
NCT07640893Von Willebrand Disease (VWD)
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Not yet open
Subthalamic Nucleus Versus Globus Pallidal Internus Deep Brain Stimulation for Parkinson Disease
NCT07250685PD - Parkinson's Disease
Zhang Jianguo
Not applicable
86
Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou
2025-11-24
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 1/2
152
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang
2025-11-24
By invitation
Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
NCT07514728Breast Cancer, Lung Metastasis, Hyperbaric Oxygen Therapy
Jinan Central Hospital
Not applicable
10
Jinan
2025-11-24
Recruiting
GenSci139 in Patients With Advanced Solid Tumors
NCT07230977Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
280
Jinan
2025-11-19
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388Limited Stage Small-Cell Lung Cancer
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
NCT07361003Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
464
Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou
2025-11-12
Recruiting
Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score
NCT07257796Intestinal Metaplasia of Gastric Mucosa, Artificial Intelligence, Endoscopy
Qilu Hospital of Shandong University
Observational
3,000
Jinan
2025-11-01
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
BioNTech SE
Phase 3
558
Changde, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Neijiang
2025-10-30
Recruiting
Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients
NCT07271849Postoperative Pain, Acute, Hemodynamics, Total Knee Arthroplasty (TKA)
Qianfoshan Hospital
Phase 4
162
Jinan
2025-10-28
Recruiting
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
NCT07296705Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital
Phase 2
25
Fuzhou, Putian, Quanzhou, Sanming, Xiamen, Zhangzhou, Nanchang, Jinan
2025-10-25
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
600
Nanchang, Beijing, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nantong
2025-10-24
Recruiting
Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
NCT07469267Breast Cancer, Radiotherapy
Fudan University
Not applicable
1,608
Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan
2025-10-24
Recruiting
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
NCT07272434Respiratory Syncytial Virus (RSV)
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT07170995Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
460
Jinan
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2025-10-16
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Active, closed
SH-SDU Shandong Endometriosis Reproductive Cohort
NCT07558629Endometriosis, Omics, Assisted Reproductive Technology
The Second Hospital of Shandong University
Observational
5,000
Jinan
2025-10-14
Recruiting
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
NCT07051486Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
60
Fuzhou, Jinan
2025-10-11
Recruiting
An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorder Through Nature-Based Tourism Activities
NCT07180342Major Depressive Disorder
Shandong Provincial Hospital
Not applicable
86
Jinan
2025-10-09
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106Breast Cancer
Genentech, Inc.
Phase 1/2
285
Jinan, Shanghai, Tianjin, Nanning
2025-10-07
Active, closed
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
NCT07173387Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2
42
Jinan
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hangzhou, Jinan, Jingzhou
2025-10-01
By invitation
An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
NCT07274579Digestive Oncology
Nanfang Hospital, Southern Medical University
Observational
2,000
Guangzhou, Jinan
2025-10-01
Not yet open
Cost Profile and Budget Implications of Rechargeable Versus Non-rechargeable Sacral Neuromodulation Devices for Neurogenic Lower Urinary Tract Dysfunction
NCT07173517Rechargeable Sacral Neuromodulation Device, Neurogenic Lower Urinary Tract Dysfunction
Qilu Hospital of Shandong University
Observational
268
Jinan
2025-10-01
Recruiting
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
NCT07185373Primary Central Nervous System Lymphoma
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
By invitation
Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer
NCT07488312Gastric Cancer
Qilu Hospital of Shandong University
Phase 1
37
Jinan
2025-10-01
Recruiting
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
NCT07007182Gastric Adenocarcinoma, Stomach Neoplasms
Jinbo Yue
Phase 2
54
Jinan
2025-10-01
Not yet open
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
NCT07206264Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
45
Fuzhou, Shijiazhuang, Harbin, Jinan, Tianjin
2025-10
Not yet open
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
NCT07135141Severe Obesity
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Not yet open
A Phase 3 Study of HS-20094 in Patients With T2DM
NCT07156539Type 2 Diabetes
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
546
Jinan, Tianjin
2025-09-30
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Not yet open
QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
NCT07156682Colon Cancer, MSS/pMMR, QL1706
Qilu Hospital of Shandong University
Phase 2
21
Jinan
2025-09-25
Not yet open
TAS-102 Plus Radiotherapy in Elderly ESCC
NCT07196345ESCC, TAS 102, Radiotherapy
Qianfoshan Hospital
Phase 1/2
45
Jinan
2025-09-25
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
Guangzhou, Harbin, Zhengzhou, Jinan
2025-09-23
Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
WestVac Biopharma Co., Ltd.
Phase 2
60
Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai
2025-09-19
Recruiting
The Effect of Proton Pump Inhibitors(PPIs) on Endoscopic Treatment of Walled-off Necrosis (WON)
NCT07488299Pancreatic Walled-off Necrosis
Qilu Hospital of Shandong University
Not applicable
120
Jinan
2025-09-17
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Recruiting
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
NCT07106892Colorectal Cancer (CRC)
Shanghai Henlius Biotech
Phase 2
60
Beijing, Jinan
2025-09-15
Recruiting
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
NCT07284992Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
Shandong Provincial Hospital
Phase 2
208
Jinan
2025-09-12
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial
NCT07179159HELICOBACTER PYLORI INFECTIONS
Yanqing Li
Not applicable
372
Jinan
2025-09-09
Recruiting
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
NCT07129382Plaque Psoriasis
Chipscreen Biosciences, Ltd.
Phase 1/2
220
Beijing, Chengde, Shijiazhuang, Shiyan, Jinan, Taiyuan, Xi’an, Hangzhou
2025-09-08
Recruiting
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
NCT07099430Advanced Melanoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
200
Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan, Shanghai
2025-09-05
Recruiting
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
NCT07093814Glioblastoma
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1/2
42
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhuhai, Nanning, Jinan
2025-09-02
Recruiting
A Phase I Study of KLA318-2 Nanocrystal Injection
NCT07171034Healthy Participants
Hunan Kelun Pharmaceutical Co., Ltd.
Phase 1
48
Jinan
2025-09-01
Recruiting
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
NCT07530770Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
Qianfoshan Hospital
Observational
20
Jinan
2025-09-01
Recruiting
An Artificial Intelligence System for Multimodal, Multi-class Diagnosing Solid Pancreatic Lesions Based on Endoscopic Ultrasound
NCT07381192Endoscopic Ultrasound (EUS), Solid Pancreatic Lesion
Qilu Hospital of Shandong University
Observational
383
Jinan
2025-09-01
Recruiting
Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs
NCT07136701Pancreatic Neuroendocine Neoplasms (pNETs)
Qilu Hospital of Shandong University
Observational
600
Jinan
2025-08-31
Not yet open
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
NCT07116577mCRC
Jinan Central Hospital
Phase 2
37
Jinan
2025-08-31
Recruiting
A Study of SKB518 in Patients With Lung Cancer
NCT07019675Lung Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
192
Shenzhen, Nanning, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanchang, Jinan
2025-08-29
Recruiting
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
Prospective Pathology Foundation Models
NCT07157618Pancancer
Nanfang Hospital, Southern Medical University
Observational
2,000
Guangzhou, Jinan
2025-08-28
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
Climb Bio, Inc.
Phase 2
45
Beijing, Shenzhen, Wuxi, Xi'an, Jinan, Yantai, Yibin
2025-08-25
Recruiting
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT07133750CRC (Colorectal Cancer)
Biotheus Inc.
Phase 2
100
Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2025-08-19
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
NCT07600268Pancreatic Cancer Non-resectable
Shandong Cancer Hospital and Institute
Phase 2
24
Jinan
2025-08-14
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Active, closed
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633Hepatocellular Carcinoma
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
NCT07391839Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
Suzhou Mednovo Yi Medical Technology Co., Ltd.
Phase 1
40
Hefei, Fuzhou, Guangzhou, Nanjing, Jinan, Hangzhou, Henan, Shanghai
2025-08-04
Recruiting
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
NCT07154316Colorectal Cancer
Fudan University
Phase 2
138
Fuzhou, Anyang, Jinan, Kunming, Shanghai
2025-08-01
Recruiting
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis
NCT07111572Ulcerative Colitis (UC), Fecal Calprotetin, FIT
Qilu Hospital of Shandong University
Observational
100
Jinan
2025-08-01
Recruiting
DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis
NCT07111273Ulcerative Colitis (UC), Fecal Calprotetin, FIT, Biomarker
Qilu Hospital of Shandong University
Observational
100
Jinan
2025-08-01
By invitation
Retrospective Pathology Foundation Models
NCT07239297Pancancer
Nanfang Hospital, Southern Medical University
Observational
2,000
Guangzhou, Jinan
2025-08-01
Not yet open
Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period
NCT07066059Perioperative Period
Shandong University
Phase EARLY_PHASE1
80
Jinan
2025-08-01
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1
434
Beijing, Chongqing, Jinan
2025-07-31
Not yet open
A Prospective, Multicenter, Observational Study of the Safety and Efficacy of Emergency Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis
NCT07108478Severe Aortic Valve Stenosis
Qilu Hospital of Shandong University
Observational
35
Jinan
2025-07-30
Recruiting
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
NCT06850090Rectal Cancer, Rectal Cancer Patients
Shandong Cancer Hospital and Institute
Phase 3
210
Jinan
2025-07-30
Recruiting
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
NCT07172685Prostate Cancer
Qilu Hospital of Shandong University
Not applicable
116
Jinan
2025-07-30
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013Immune Thrombocytopenia (ITP)
Eli Lilly and Company
Phase 1/2
68
Guangzhou, Jinan, Tianjin, Wuhan
2025-07-30
Recruiting
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
NCT07079475Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Shengyang, Jinan
2025-07-30
Recruiting
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT07061535Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Changsha, Jinan, Hangzhou
2025-07-30
Recruiting
EIT-guided PEEP Titration Versus Standard Ventilation in Bariatric Surgery
NCT07207772Electrical Impedance Tomography (EIT), Postoperative Pulmonary Complications (PPCs), Recruitment, Mechanical Ventilation Complication
Jianbo Wu
Not applicable
118
Jinan
2025-07-28
Recruiting
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
NCT07089199NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel
Qilu Hospital of Shandong University
Phase 2
34
Jinan
2025-07-25
Recruiting
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
NCT07062055Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
Shandong Cancer Hospital and Institute
Phase 2
54
Jinan
2025-07-25
Recruiting
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
NCT06918834Myelodysplastic Syndromes
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
236
Beijin, Zhengzhou, Jinan, Chengdu, Shijia Zhuang
2025-07-24
Recruiting
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
NCT06841172OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
Shandong Cancer Hospital and Institute
Phase 3
132
Jinan
2025-07-21
Not yet open
Antarctic Krill Oil Functional Food Mitigates Bladder Cancer Treatment Side Effects
NCT06880939Urinary Bladder Neoplasms
Qilu Hospital of Shandong University
Not applicable
210
Jinan
2025-07-15
Recruiting
Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial
NCT06834971Ventilator-Associated Pneumonia (VAP)
Qilu Hospital of Shandong University
Not applicable
508
Jinan
2025-07-15
Recruiting
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
NCT07202728Hydatidiform Mole
Obstetrics & Gynecology Hospital of Fudan University
Observational
1,489
Lanzhou, Shenzhen, Haikou, Shijiazhuang, Zhengzhou, Dalian, Shenyang, Jinan
2025-07-09
Recruiting
MITRIS China Post Market Clinical Follow-up (PMCF) Study
NCT07059793Mitral Valve Replacement
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan
2025-07-08
Recruiting
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
NCT07028281Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
120
Jinan
2025-07-08
Recruiting
Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
NCT07309211SCLC, Limited Stage
The First Affiliated Hospital with Nanjing Medical University
Observational
25
Jinan, Nanjing, Qingdao
2025-07-08
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
RAB Versus Ultrathin Bronchoscopy With VBN in the Diagnosis of PPNs
NCT06962436Peripheral Pulmonary Nodules
Shanghai Chest Hospital
Not applicable
186
Jinan, Shanghai, Hangzhou
2025-07-02
Recruiting
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
NCT07030140Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer
Jinbo Yue
Phase 2
38
Jinan
2025-07-01
Not yet open
Comparison of the GMA-TULIP and I-gel Laryngeal Mask for Airway Management in General Anaesthesia: a Randomized Controlled Trial
NCT07019961Trauma Surgery, General Anesthesia
Qilu Hospital of Shandong University
Not applicable
198
Jinan
2025-07-01
Recruiting
Research on the Optimization of Treatment for Spinal Metastases With Radioactive Particle Implantation Using TPS and Mechanical Dual Simulation
NCT07171996Bone Metastases in Subjects With Advanced Cancer
Li Min
Not applicable
150
Jinan
2025-07-01
Recruiting
Fungal Status and Prognosis in ABPA
NCT07690345ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Colonization
Qianfoshan Hospital
Observational
114
Jinan
2025-07-01
Recruiting
Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study
NCT07045467Chronic Kidney Diseases, Renal Transplantation
Qianfoshan Hospital
Phase 1
30
Jinan
2025-07-01
Not yet open
BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
NCT07008053Marginal Zone Lymphomas
Tianjin Medical University Cancer Institute and Hospital
Phase 2
37
Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin
2025-07
Recruiting
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
NCT07071090Solid Tumor Malignancies
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Rows per page Showing 201–300 of 785
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/jinan?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 785 of those studies with a site in Jinan.

How many clinical trials are recruiting in Jinan?

488 of the 785 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 130 have not yet opened recruitment, 149 are active but closed to new participants, and 18 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.